Cost-utility analysis of venetoclax in combination with obinutuzumab as first-line treatment of chronic lymphocytic leukaemia in Spain

被引:0
作者
Moreno-Martinez, Estela [1 ]
de la Serna-Torroba, Javier [2 ]
Escudero-Vilaplana, Vicente [3 ]
Angel Hernandez-Rivas, Jose [4 ]
Sanchez-Cuervos, Marina [5 ]
Sanchez-Hernandez, Raquel [6 ]
机构
[1] Hosp Santa Creu & Sant Pau, Serv Farm, Barcelona, Spain
[2] Hosp Univ 12 Octubre, Serv Hematol, Madrid, Spain
[3] Hosp Univ Gregorio Maranon, Serv Farm, Madrid, Spain
[4] Hosp Univ Infanta Leonor, Serv Hematol, Madrid, Spain
[5] Hosp Univ Ramon y Cajal, Serv Farm, Madrid, Spain
[6] AbbVie Spain SLU, Madrid, Spain
关键词
Chronic lymphocytic leukaemia; Efficiency; Economic evaluation; Quality of life; Venetoclax; CLINICAL-TRIAL DATA; ECONOMIC-EVALUATION; SURVIVAL ANALYSIS; OPEN-LABEL; FLUDARABINE; CYCLOPHOSPHAMIDE; RITUXIMAB; IBRUTINIB; PHASE-3;
D O I
10.7399/fh.11829
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Venetoclax in combination with obinutuzumab has significantly improved efficacy versus immunochemotherapy (progression-free survival) in patients with chronic lymphocytic leukaemia who have not received prior treatment. The objective of this study was to evaluate its efficiency in Spain using a cost-utility analysis. Method: Using a partitioned-survival analysis model adapted to the Spanish context and based on three health states (progression-free survival, survival after progression, and death), a simulation of the evolution of patients who were candidates for initiating first-line treatment was conducted for a lifetime time horizon. Venetoclax in combination with obinutuzumab was compared to the most commonly used therapeutic options for these patients at the time of study design: chlorambucil in combination with obinutuzumab, ibrutinib, fludarabine in combination with cyclophosphamide and rituximab, and bendamustine in combination with rituximab. In order to estimate survival curves, efficacy data were derived from the CLL14 trial and a network meta-analysis. The analysis was conducted from the perspective of the Spanish National Healthcare System and included direct healthcare costs (i.e. pharma-cological costs and their administration), and those associated with the management of the disease and adverse events. The resource use was validated by an expert group. Quality of life data were used to estimate the quality-adjusted life years obtained for each alternative. A threshold of euro 25,000/quality-adjusted life years was used. The robustness of the model was evaluated using deterministic and probabilistic sensitivity analyses. Results: Venetoclax in combination with obinutuzumab was shown to be a dominant alternative compared to the rest of the treatment alternati-ves, with a lower cost per patient (euro -67,869 compared to chlorambucil in combination with obinutuzumab, euro -375,952 compared to ibrutinib, euro -61,996 compared to fludarabine in combination with cyclophospha-mide and rituximab, and euro -77,398 compared to bendamustine in com-bination with rituximab). It also had a greater gain in quality-adjusted life years (0.551 quality-adjusted life years gained compared to chlorambucil in combination with obinutuzumab and ibrutinib, 1.639 quality-adjusted life years gained compared to fludarabine in combination with cyclo-phosphamide and rituximab, and 1.186 quality-adjusted life years gained compared to bendamustine in combination with rituximab). Between 68% and 85% of the simulations performed in the sensitivity analysis showed that venetoclax in combination with obinutuzumab had lower costs and more quality-adjusted life years gained. Conclusions: Venetoclax in combination with obinutuzumab is an effi-cient and dominant alternative for treating previously untreated patients with chronic lymphocytic leukaemia compared to the available alterna-tives and from the perspective of the Spanish National Health System.
引用
收藏
页码:121 / 132
页数:12
相关论文
共 42 条
  • [1] High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia
    Al-Sawaf, Othman
    Lilienweiss, Esther
    Bahlo, Jasmin
    Robrecht, Sandra
    Fink, Anna-Maria
    Patz, Michaela
    Tandon, Maneesh
    Jiang, Yanwen
    Schary, William
    Ritgen, Matthias
    Tausch, Eugen
    Stilgenbauer, Stephan
    Eichhorst, Barbara
    Fischer, Kirsten
    Hallek, Michael
    Kreuzer, Karl-Anton
    [J]. BLOOD, 2020, 135 (11) : 866 - 870
  • [2] [Anonymous], GUIAS TRATAMIENTO LL
  • [3] Survival Analysis and Extrapolation Modeling of Time-to-Event Clinical Trial Data for Economic Evaluation: An Alternative Approach
    Bagust, Adrian
    Beale, Sophie
    [J]. MEDICAL DECISION MAKING, 2014, 34 (03) : 343 - 351
  • [4] Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p
    Barnes, James, I
    Divi, Vasu
    Begaye, Adrian
    Wong, Russell
    Coutre, Steven
    Owens, Douglas K.
    Goldhaber-Fiebert, Jeremy D.
    [J]. BLOOD ADVANCES, 2018, 2 (15) : 1946 - 1956
  • [5] Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2
    Barr, Paul M.
    Robak, Tadeusz
    Owen, Carolyn
    Tedeschi, Alessandra
    Bairey, Osnat
    Bartlett, Nancy L.
    Burger, Jan A.
    Hillmen, Peter
    Coutre, Steven
    Devereux, Stephen
    Grosicki, Sebastian
    McCarthy, Helen
    Li, Jianyong
    Simpson, David
    Offner, Fritz
    Moreno, Carol
    Zhou, Cathy
    Styles, Lori
    James, Danelle
    Kipps, Thomas J.
    Ghia, Paolo
    [J]. HAEMATOLOGICA, 2018, 103 (09) : 1502 - 1510
  • [6] Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study
    Beusterien, Kathleen M.
    Davies, John
    Leach, Michael
    Meiklejohn, David
    Grinspan, Jessica L.
    O'Toole, Alison
    Bramham-Jones, Steve
    [J]. HEALTH AND QUALITY OF LIFE OUTCOMES, 2010, 8
  • [7] Handling uncertainty in cost-effectiveness models
    Briggs, AH
    [J]. PHARMACOECONOMICS, 2000, 17 (05) : 479 - 500
  • [8] Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
    Burger, Jan A.
    Barr, Paul M.
    Robak, Tadeusz
    Owen, Carolyn
    Ghia, Paolo
    Tedeschi, Alessandra
    Bairey, Osnat
    Hillmen, Peter
    Coutre, Steven E.
    Devereux, Stephen
    Grosicki, Sebastian
    McCarthy, Helen
    Simpson, David
    Offner, Fritz
    Moreno, Carol
    Dai, Sandra
    Lal, Indu
    Dean, James P.
    Kipps, Thomas J.
    [J]. LEUKEMIA, 2020, 34 (03) : 787 - 798
  • [9] Up to 7 Years of Follow-up of Single-Agent Ibrutinib in the Phase 1b/2 PCYC-1102 Trial of First Line and Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Byrd, John C.
    Furman, Richard R.
    Coutre, Steven
    Flinn, Ian W.
    Burger, Jan A.
    Blum, Kristie A.
    Sharman, Jeff
    Wierda, William G.
    Zhao, Weiqiang
    Heerema, Nyla A.
    Luan, Ying
    Liu, Emily A.
    Dean, James P.
    O'Brien, Susan M.
    [J]. BLOOD, 2018, 132
  • [10] Consejo General de Colegios Oficiales de Farmaceuticos, 2020, PORT FARM BOTPLUS